SCHEMBL15979571

SCHEMBL15979571

Cc1cc(F)ccc1N1CCN(C(=O)c2cc3[nH]c(=O)c4ccccc4n3c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.46
POLB P06746 2/20 0.46
TSHR P16473 3/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.43
SPR P35270 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PARP1 P09874 4/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
THRB P10828 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
MGLL Q99685 3/20 0.41
NPY2R P49146 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14647232 0.91 SPR (0.52) HTTPOLBTSHRMAPTLMNA
SCHEMBL15979570 0.89 ALOX15 (0.48) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647236 0.88 MAPT (0.47) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647210 0.85 ALDH1A1 (0.55) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647202 0.85 MAPT (0.56) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647261 0.84 MGLL (0.49) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647120 0.83 POLB (0.55) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647214 0.83 CYP3A4 (0.39) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647178 0.82 MAPT (0.52) HTTPOLBTSHRMAPTLMNA
SCHEMBL14647161 0.81 MGLL (0.52) POLBTSHRMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062061-B2 Compound having PARP inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-23 US disclosed
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY PARP1, PARP11, PARP2 HTT 3723/4885POLB 75/4885TSHR 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.